CN102993311B - 鸡ibd病毒vp2蛋白和ltb的融合蛋白及其应用 - Google Patents
鸡ibd病毒vp2蛋白和ltb的融合蛋白及其应用 Download PDFInfo
- Publication number
- CN102993311B CN102993311B CN201210509085.7A CN201210509085A CN102993311B CN 102993311 B CN102993311 B CN 102993311B CN 201210509085 A CN201210509085 A CN 201210509085A CN 102993311 B CN102993311 B CN 102993311B
- Authority
- CN
- China
- Prior art keywords
- protein
- ltb
- immune
- vaccine
- virus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 101710081079 Minor spike protein H Proteins 0.000 title abstract description 25
- 208000015181 infectious disease Diseases 0.000 title abstract description 11
- 108090000623 proteins and genes Proteins 0.000 title abstract description 11
- 208000027312 Bursal disease Diseases 0.000 title abstract description 9
- 241000700605 Viruses Species 0.000 title abstract description 9
- 230000002458 infectious effect Effects 0.000 title abstract description 9
- 102000004169 proteins and genes Human genes 0.000 title abstract 5
- 238000001802 infusion Methods 0.000 title abstract 4
- 150000002617 leukotrienes Chemical class 0.000 title abstract 2
- 230000004927 fusion Effects 0.000 claims abstract description 25
- 229940031626 subunit vaccine Drugs 0.000 claims abstract description 20
- 241000588724 Escherichia coli Species 0.000 claims abstract description 17
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract description 7
- 239000000147 enterotoxin Substances 0.000 claims abstract description 6
- 231100000655 enterotoxin Toxicity 0.000 claims abstract description 6
- 239000002773 nucleotide Substances 0.000 claims description 9
- 125000003729 nucleotide group Chemical group 0.000 claims description 9
- 101500001532 Avian infectious bursal disease virus Capsid protein VP2 Proteins 0.000 claims description 3
- 241000287828 Gallus gallus Species 0.000 abstract description 20
- 235000013330 chicken meat Nutrition 0.000 abstract description 20
- 229960005486 vaccine Drugs 0.000 abstract description 11
- 241000702626 Infectious bursal disease virus Species 0.000 abstract description 9
- 230000036039 immunity Effects 0.000 abstract description 8
- 231100000614 poison Toxicity 0.000 abstract description 5
- 210000002966 serum Anatomy 0.000 abstract description 5
- 101710146739 Enterotoxin Proteins 0.000 abstract description 4
- 210000004698 lymphocyte Anatomy 0.000 abstract description 4
- 230000009466 transformation Effects 0.000 abstract description 4
- 229920001817 Agar Polymers 0.000 abstract description 3
- 239000008272 agar Substances 0.000 abstract description 3
- 239000000568 immunological adjuvant Substances 0.000 abstract description 3
- 210000004369 blood Anatomy 0.000 abstract description 2
- 239000008280 blood Substances 0.000 abstract description 2
- 230000000951 immunodiffusion Effects 0.000 abstract description 2
- 230000005847 immunogenicity Effects 0.000 abstract description 2
- 239000003440 toxic substance Substances 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 description 12
- 239000012634 fragment Substances 0.000 description 11
- 239000003921 oil Substances 0.000 description 11
- 230000003321 amplification Effects 0.000 description 8
- 238000003199 nucleic acid amplification method Methods 0.000 description 8
- 239000013612 plasmid Substances 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 6
- 210000001669 bursa of fabricius Anatomy 0.000 description 6
- 230000008859 change Effects 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 238000000137 annealing Methods 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 230000001954 sterilising effect Effects 0.000 description 5
- 241000894006 Bacteria Species 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 4
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 230000004087 circulation Effects 0.000 description 4
- 239000002574 poison Substances 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 238000011144 upstream manufacturing Methods 0.000 description 4
- 239000002671 adjuvant Substances 0.000 description 3
- CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical class [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 238000004925 denaturation Methods 0.000 description 3
- 230000036425 denaturation Effects 0.000 description 3
- 239000012154 double-distilled water Substances 0.000 description 3
- 238000001962 electrophoresis Methods 0.000 description 3
- 238000010353 genetic engineering Methods 0.000 description 3
- 239000003292 glue Substances 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 3
- 229910001629 magnesium chloride Inorganic materials 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 3
- 229920000053 polysorbate 80 Polymers 0.000 description 3
- 230000004224 protection Effects 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 108091008146 restriction endonucleases Proteins 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 238000013519 translation Methods 0.000 description 3
- FRXSZNDVFUDTIR-UHFFFAOYSA-N 6-methoxy-1,2,3,4-tetrahydroquinoline Chemical compound N1CCCC2=CC(OC)=CC=C21 FRXSZNDVFUDTIR-UHFFFAOYSA-N 0.000 description 2
- 208000030507 AIDS Diseases 0.000 description 2
- 101150076489 B gene Proteins 0.000 description 2
- 206010062016 Immunosuppression Diseases 0.000 description 2
- 238000012408 PCR amplification Methods 0.000 description 2
- 101710194807 Protective antigen Proteins 0.000 description 2
- 229920002684 Sepharose Polymers 0.000 description 2
- 101150093578 VP2 gene Proteins 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000000688 enterotoxigenic effect Effects 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 210000003608 fece Anatomy 0.000 description 2
- 238000000265 homogenisation Methods 0.000 description 2
- 150000002460 imidazoles Chemical class 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 230000001506 immunosuppresive effect Effects 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 239000010977 jade Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000012797 qualification Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 210000002345 respiratory system Anatomy 0.000 description 2
- 238000010839 reverse transcription Methods 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 239000007929 subcutaneous injection Substances 0.000 description 2
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 241001260012 Bursa Species 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 102000012410 DNA Ligases Human genes 0.000 description 1
- 108010061982 DNA Ligases Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 238000002768 Kirby-Bauer method Methods 0.000 description 1
- 108010076039 Polyproteins Proteins 0.000 description 1
- 101000933967 Pseudomonas phage KPP25 Major capsid protein Proteins 0.000 description 1
- 108020000999 Viral RNA Proteins 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000000240 adjuvant effect Effects 0.000 description 1
- 230000010100 anticoagulation Effects 0.000 description 1
- 230000027645 antigenic variation Effects 0.000 description 1
- 229940031567 attenuated vaccine Drugs 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 210000003711 chorioallantoic membrane Anatomy 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 230000001571 immunoadjuvant effect Effects 0.000 description 1
- 229940031551 inactivated vaccine Drugs 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000012460 protein solution Substances 0.000 description 1
- 230000012743 protein tagging Effects 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000004088 simulation Methods 0.000 description 1
- 238000003307 slaughter Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 210000005239 tubule Anatomy 0.000 description 1
- 238000002525 ultrasonication Methods 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 239000002435 venom Substances 0.000 description 1
- 231100000611 venom Toxicity 0.000 description 1
- 210000001048 venom Anatomy 0.000 description 1
- 230000001018 virulence Effects 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Landscapes
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210509085.7A CN102993311B (zh) | 2012-12-03 | 2012-12-03 | 鸡ibd病毒vp2蛋白和ltb的融合蛋白及其应用 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210509085.7A CN102993311B (zh) | 2012-12-03 | 2012-12-03 | 鸡ibd病毒vp2蛋白和ltb的融合蛋白及其应用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102993311A CN102993311A (zh) | 2013-03-27 |
| CN102993311B true CN102993311B (zh) | 2014-07-09 |
Family
ID=47922470
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201210509085.7A Active CN102993311B (zh) | 2012-12-03 | 2012-12-03 | 鸡ibd病毒vp2蛋白和ltb的融合蛋白及其应用 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102993311B (zh-TW) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103483449A (zh) * | 2013-08-20 | 2014-01-01 | 东北农业大学 | 两种scFv抗体、其编码基因及其在制备治疗或预防鸡传染性法氏囊病制剂中的应用 |
| CN106754743B (zh) * | 2016-11-17 | 2020-06-02 | 河南农业大学 | 超强毒力鸡传染性法氏囊病病毒细胞适应毒株及其应用 |
| CN107485712A (zh) * | 2017-08-09 | 2017-12-19 | 扬州优邦生物药品有限公司 | 一种猪伪狂犬病毒亚单位疫苗及其制备方法和应用 |
| CN109134668A (zh) * | 2018-09-19 | 2019-01-04 | 天康生物股份有限公司 | 鸡传染性法氏囊病病毒的融合蛋白及其制备方法、应用、表达系统和疫苗 |
| CN114107227B (zh) * | 2021-11-04 | 2022-09-06 | 扬州优邦生物药品有限公司 | 一种同时表达经典株和变异株传染性法氏囊病毒vp2蛋白的重组火鸡疱疹病毒活载体疫苗 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102688487A (zh) * | 2012-06-18 | 2012-09-26 | 青岛易邦生物工程有限公司 | 鸡新城疫、传染性支气管炎、传染性法氏囊病、病毒性关节炎四联灭活疫苗的生产方法 |
-
2012
- 2012-12-03 CN CN201210509085.7A patent/CN102993311B/zh active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102688487A (zh) * | 2012-06-18 | 2012-09-26 | 青岛易邦生物工程有限公司 | 鸡新城疫、传染性支气管炎、传染性法氏囊病、病毒性关节炎四联灭活疫苗的生产方法 |
Non-Patent Citations (4)
| Title |
|---|
| 乳酸菌融合表达传染性法氏囊病毒VP2 蛋白与大肠杆菌LTB 及其诱导免疫应答的研究;唐丽杰 等;《中国预防兽医学报》;20120731;第34卷(第7期);第576－580页 * |
| 传染性法氏囊病病毒结构的分子生物学研究进展;裴超信等;《西南民族大学学报(自然科学版)》;20051231;全文 * |
| 唐丽杰 等.乳酸菌融合表达传染性法氏囊病毒VP2 蛋白与大肠杆菌LTB 及其诱导免疫应答的研究.《中国预防兽医学报》.2012,第34卷(第7期),第576－580页. |
| 裴超信等.传染性法氏囊病病毒结构的分子生物学研究进展.《西南民族大学学报(自然科学版)》.2005, |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102993311A (zh) | 2013-03-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102993311B (zh) | 鸡ibd病毒vp2蛋白和ltb的融合蛋白及其应用 | |
| CN107033250B (zh) | 牛冠状病毒重组多表位抗原及其应用 | |
| CN102994520B (zh) | 鸡传染性法氏囊病vp2基因及其应用 | |
| CN117482220A (zh) | 一种传染性法氏囊病病毒变异株的vp2蛋白亚单位疫苗及其制备方法和应用 | |
| CN102993310B (zh) | 鸡ibd病毒vp2和鸡il-2的融合蛋白及其应用 | |
| CN107488234A (zh) | 禽腺病毒Hexon与鸡传染性法氏囊病病毒VP2融合抗原、亚单位疫苗及其制备方法 | |
| CN103275228A (zh) | K99-987p-f41重组蛋白及其应用 | |
| CN113855795B (zh) | 禽戊型肝炎病毒orf2亚单位疫苗 | |
| CN104610455B (zh) | 一种鸭坦布苏病毒基因工程亚单位疫苗 | |
| CN104250304B (zh) | 一种融合蛋白及其编码的疫苗组合物与应用 | |
| CN104548087B (zh) | 一种抗a/b亚群禽白血病病毒感染的表位疫苗及其制备方法和应用 | |
| CN103626878B (zh) | 鸡新城疫病毒f蛋白和肠毒素ltb的融合蛋白及应用 | |
| CN102973930B (zh) | 一种鸡亚单位二联疫苗及其制备和应用 | |
| CN101481675B (zh) | 一种抗猪瘟多表位dna疫苗及构建方法和应用 | |
| CN103007271B (zh) | 一种鸡亚单位四联疫苗及其制备和应用 | |
| CN115340609A (zh) | 一种口蹄疫病毒多抗原表位融合蛋白、蛋白笼纳米颗粒及其制备方法 | |
| CN102603898B (zh) | 与i群禽腺病毒免疫相关融合蛋白及其编码基因与应用 | |
| CN116496362A (zh) | 一种猪轮状病毒的抗原组合及其应用 | |
| CN105085625A (zh) | 一种兼抗肠道病毒71和柯萨奇病毒a16的基因工程疫苗 | |
| CN102973935A (zh) | 一种鸡亚单位三联疫苗及其制备和应用 | |
| WO2017088448A1 (zh) | 一种登革热双效疫苗的制备方法及其应用 | |
| WO2015039270A1 (zh) | 蛋白a1g_07050在抗立氏立克次体的免疫保护中的应用 | |
| WO2005021035A1 (fr) | Vaccin peptidique bivalent dirige contre fmd, ses procedes de preparation et ses applications | |
| CN102604898B (zh) | 携带o型口蹄疫病毒b细胞表位的vp60蛋白重组杆状病毒 | |
| CN113136356A (zh) | 一种重组链球菌及其制备方法和应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C53 | Correction of patent of invention or patent application | ||
| CB02 | Change of applicant information |
Address after: 266111 Shandong city of Qingdao province Chengyang Qingda Industrial Park, the first northbound dual Applicant after: QINGDAO VLAND BIOTECH Inc. Applicant after: QINGDAO BOITE BIOPHARMACEUTICAL Co.,Ltd. Address before: 266061 Shandong city of Qingdao province high tech park of Laoshan district by the No. 29 Shandong Road, building 6F high speed Applicant before: QINGDAO KDN PHARMACEUTICAL Co.,Ltd. Applicant before: QINGDAO BOITE BIOPHARMACEUTICAL Co.,Ltd. |
|
| COR | Change of bibliographic data |
Free format text: CORRECT: APPLICANT; FROM: QINGDAO KDN PHARMACEUTICAL CO., LTD. TO: QINGDAO WEILAN BIOLOGY CO., LTD. |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C56 | Change in the name or address of the patentee | ||
| CP01 | Change in the name or title of a patent holder |
Address after: 266111 Shandong city of Qingdao province Chengyang Qingda Industrial Park, the first northbound dual Patentee after: QINGDAO VLAND BIOTECH Inc. Patentee after: QINGDAO VLAND BIOTECH GROUP CO.,LTD. Address before: 266111 Shandong city of Qingdao province Chengyang Qingda Industrial Park, the first northbound dual Patentee before: QINGDAO VLAND BIOTECH Inc. Patentee before: QINGDAO BOITE BIOPHARMACEUTICAL Co.,Ltd. |
|
| CP01 | Change in the name or title of a patent holder |
Address after: 266111 north head of Shuangyuan Road, Qingda Industrial Park, Chengyang District, Qingdao City, Shandong Province Patentee after: QINGDAO VLAND BIOTECH Inc. Patentee after: Qingdao Blue Animal Health Group Co.,Ltd. Address before: 266111 north head of Shuangyuan Road, Qingda Industrial Park, Chengyang District, Qingdao City, Shandong Province Patentee before: QINGDAO VLAND BIOTECH Inc. Patentee before: QINGDAO VLAND BIOTECH GROUP CO.,LTD. |
|
| CP01 | Change in the name or title of a patent holder |